Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine.
about
Mucosal vaccination with a multivalent, live-attenuated vaccine induces multifactorial immunity against Pseudomonas aeruginosa acute lung infection.Oral vaccination of BALB/c mice with Salmonella enterica serovar Typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model.Evaluation of flagella and flagellin of Pseudomonas aeruginosa as vaccines.Synthetic {beta}-(1->6)-linked N-acetylated and nonacetylated oligoglucosamines used to produce conjugate vaccines for bacterial pathogensSerodiversity of opsonic antibodies against Enterococcus faecalis--glycans of the cell wall revisited.Recombinant Shiga toxin B-subunit-keyhole limpet hemocyanin conjugate vaccine protects mice from Shigatoxemia.Animal and human antibodies to distinct Staphylococcus aureus antigens mutually neutralize opsonic killing and protection in mice.Nonmucoid Pseudomonas aeruginosa expresses alginate in the lungs of patients with cystic fibrosis and in a mouse model.Efficacy of a conjugate vaccine containing polymannuronic acid and flagellin against experimental Pseudomonas aeruginosa lung infection in mice.Elucidation of structural and antigenic properties of pneumococcal serotype 11A, 11B, 11C, and 11F polysaccharide capsules.Streptococcus pneumoniae serotype 9A isolates contain diverse mutations to wcjE that result in variable expression of serotype 9V-specific epitopeStructural characterization of Streptococcus pneumoniae serotype 9A capsule polysaccharide reveals role of glycosyl 6-O-acetyltransferase wcjE in serotype 9V capsule biosynthesis and immunogenicity.Vaccines based on the cell surface carbohydrates of pathogenic bacteria.Pseudomonas aeruginosa: the potential to immunise against infection.Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.A commensal streptococcus hijacks a Pseudomonas aeruginosa exopolysaccharide to promote biofilm formation.Airway epithelial control of Pseudomonas aeruginosa infection in cystic fibrosis.Evaluation of the Immunogenicity of Diphtheria Toxoid Conjugated to Salmonella Typhimurium-Derived OPS in a Mouse Model: A Potential Vaccine Candidate Against SalmonellosisPseudomonas aeruginosa virulence and therapy: evolving translational strategies.Recent developments for Pseudomonas vaccines.Opsonic antibodies to Enterococcus faecalis strain 12030 are directed against lipoteichoic acidImmunological evaluation of an alginate-based conjugate as a vaccine candidate against Pseudomonas aeruginosa.Prophylactic and therapeutic efficacy of a fully human immunoglobulin G1 monoclonal antibody to Pseudomonas aeruginosa alginate in murine keratitis infection.Mechanism of enhanced activity of liposome-entrapped aminoglycosides against resistant strains of Pseudomonas aeruginosa.Potential targets for next generation anti-microbial glycoconjugate vaccines.
P2860
Q30430870-98C89B68-8779-48C0-8532-4C25C258D36DQ30435195-1D26D0FD-8EB6-4F18-AFD0-39F584B3A307Q33613907-1B149D81-767F-4B42-888C-3563529CC3CBQ33613913-D4606968-CD77-4D68-82D8-74F5CC972DBBQ33855583-92F273B5-E335-4233-A4F0-BF0BA2685A25Q34033376-CDEFC247-5701-40CF-997D-1DC11625EE36Q34090161-70B97A25-AF3E-4145-89E1-01D3D001BAF9Q34232085-1BD44D50-ED71-42B9-93DD-0B95B4D8AB62Q35139384-831FD3BA-1979-4C1E-823E-6392920BE8F9Q35274206-ADBB522C-75E6-4661-8E5F-0325379CBDDAQ35567399-0A185072-7147-4518-8929-8A81F2D9EE92Q35922324-99B2F7CE-47AE-4168-8C51-8B6AF029F669Q36128243-E32EFF46-6917-4668-B167-C72C2D30BA18Q36194089-878FACCE-2A6B-4155-9955-E6CC22888011Q36284542-95140FC1-4FE5-4792-843C-24F8CE589901Q36356762-58439A6B-B63F-48F9-B3BB-C5EF56A9F787Q36968815-AB3E9BFA-C59F-46C2-BC14-DCC9266689F3Q37263373-0ADD9880-BF52-4E12-B272-FA77331713CEQ37358382-66D7FA55-7E04-4A6F-9905-0BCA432CE5A1Q37937369-CF539102-F080-4FB2-90BC-906E94D5DDF5Q38484159-94560E70-8E0B-41F0-9103-809AB7CA47FFQ41620789-DDAC4B81-6AAF-4960-9176-5F184AB80EDDQ41909195-2658AD56-CF71-443A-B9E2-B625F79EC766Q42246881-B576994E-60C8-40BC-86EF-0308C25EC650Q53701548-885917F6-54A4-497C-ABE9-CBD4B78076C4
P2860
Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Construction and characterizat ...... de-alginate conjugate vaccine.
@ast
Construction and characterizat ...... de-alginate conjugate vaccine.
@en
type
label
Construction and characterizat ...... de-alginate conjugate vaccine.
@ast
Construction and characterizat ...... de-alginate conjugate vaccine.
@en
prefLabel
Construction and characterizat ...... de-alginate conjugate vaccine.
@ast
Construction and characterizat ...... de-alginate conjugate vaccine.
@en
P2093
P2860
P1476
Construction and characterizat ...... ide-alginate conjugate vaccine
@en
P2093
Fadie T Coleman
Martha Grout
Nicolas Llosa
Simone Mueschenborn
P2860
P304
P356
10.1128/IAI.71.7.3875-3884.2003
P407
P577
2003-07-01T00:00:00Z